Published in Carcinogenesis on February 07, 2014
Regulation of complement-dependent cytotoxicity by TGF-β-induced epithelial-mesenchymal transition. Oncogene (2015) 0.82
Bioinformatic approaches to augment study of epithelial-to-mesenchymal transition in lung cancer. Physiol Genomics (2014) 0.82
ANGPTL4 Correlates with NSCLC Progression and Regulates Epithelial-Mesenchymal Transition via ERK Pathway. Lung (2016) 0.80
Inhibition of the colony-stimulating-factor-1 receptor affects the resistance of lung cancer cells to cisplatin. Oncotarget (2016) 0.79
Immunological Consequences of Epithelial-Mesenchymal Transition in Tumor Progression. J Immunol (2016) 0.78
IL-17 induces EMT via Stat3 in lung adenocarcinoma. Am J Cancer Res (2016) 0.77
S100P interacts with integrin α7 and increases cancer cell migration and invasion in lung cancer. Oncotarget (2015) 0.77
The Role of Interleukin-17 in Lung Cancer. Mediators Inflamm (2016) 0.75
Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics (2003) 100.88
Improved prediction of signal peptides: SignalP 3.0. J Mol Biol (2004) 48.40
The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell (2008) 46.08
MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nat Biotechnol (2008) 38.00
Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci U S A (2001) 24.34
A molecular signature of metastasis in primary solid tumors. Nat Genet (2002) 21.36
Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature (2005) 19.56
An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat Genet (2008) 17.67
Diversity of gene expression in adenocarcinoma of the lung. Proc Natl Acad Sci U S A (2001) 17.36
PSORT: a program for detecting sorting signals in proteins and predicting their subcellular localization. Trends Biochem Sci (1999) 14.36
Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med (2004) 12.73
Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nat Med (2008) 10.12
Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst (2006) 8.38
Evaluation of methods for the prediction of membrane spanning regions. Bioinformatics (2001) 6.53
Reporting recommendations for tumor marker prognostic studies. J Clin Oncol (2005) 6.31
The new lung cancer staging system. Chest (2009) 6.30
Gene expression-based prognostic signatures in lung cancer: ready for clinical use? J Natl Cancer Inst (2010) 4.80
A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA non-small-cell lung cancer. Eastern Cooperative Oncology Group. N Engl J Med (2000) 4.54
Feature-based prediction of non-classical and leaderless protein secretion. Protein Eng Des Sel (2004) 4.54
Gene expression signatures for predicting prognosis of squamous cell and adenocarcinomas of the lung. Cancer Res (2006) 4.11
Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell Lung cancer. J Natl Cancer Inst (2003) 2.95
Identification of genes upregulated in ALK-positive and EGFR/KRAS/ALK-negative lung adenocarcinomas. Cancer Res (2011) 2.81
Long-term results of the international adjuvant lung cancer trial evaluating adjuvant Cisplatin-based chemotherapy in resected lung cancer. J Clin Oncol (2009) 2.50
Differential protein expression profiling by iTRAQ-2DLC-MS/MS of lung cancer cells undergoing epithelial-mesenchymal transition reveals a migratory/invasive phenotype. J Proteome Res (2006) 2.43
Chemotherapy for patients with non-small cell lung cancer: the surgical setting of the Big Lung Trial. Eur J Cardiothorac Surg (2004) 2.14
ConceptGen: a gene set enrichment and gene set relation mapping tool. Bioinformatics (2009) 2.11
MammaPrint 70-gene signature: another milestone in personalized medical care for breast cancer patients. Expert Rev Mol Diagn (2009) 1.89
New molecularly targeted therapies for lung cancer. J Clin Invest (2007) 1.86
Development and clinical utility of a 21-gene recurrence score prognostic assay in patients with early breast cancer treated with tamoxifen. Oncologist (2007) 1.78
SPD--a web-based secreted protein database. Nucleic Acids Res (2005) 1.75
New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors. Semin Oncol (2006) 1.67
Can adjuvant chemotherapy improve survival in patients with early-stage, resected non-small-cell lung cancer? Nat Clin Pract Oncol (2005) 1.40
An embryonic stem cell-like signature identifies poorly differentiated lung adenocarcinoma but not squamous cell carcinoma. Clin Cancer Res (2009) 1.38
Breaking a vicious cycle. Sci Transl Med (2013) 1.36
Development and validation of a quantitative real-time polymerase chain reaction classifier for lung cancer prognosis. J Thorac Oncol (2011) 1.32
Peroxisome proliferator-activated receptor-gamma activation inhibits tumor metastasis by antagonizing Smad3-mediated epithelial-mesenchymal transition. Mol Cancer Ther (2010) 1.30
Temporal quantitative proteomics by iTRAQ 2D-LC-MS/MS and corresponding mRNA expression analysis identify post-transcriptional modulation of actin-cytoskeleton regulators during TGF-beta-Induced epithelial-mesenchymal transition. J Proteome Res (2009) 1.29
ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of non-small-cell lung cancer (NSCLC). Ann Oncol (2005) 1.10
Adjuvant Chemotherapy for Early-Stage Non-small Cell Lung Cancer. Chest (2005) 1.01
Gene expression profiling of non-small-cell lung cancer. Expert Rev Mol Diagn (2008) 1.00
Standards for reporting prognostic tumor marker studies. J Clin Oncol (2005) 0.98
Quality-adjusted time without symptoms or toxicity analysis of adjuvant chemotherapy in non-small-cell lung cancer: an analysis of the National Cancer Institute of Canada Clinical Trials Group JBR.10 trial. J Clin Oncol (2009) 0.96
Identifying inhibitors of epithelial-mesenchymal transition by connectivity map-based systems approach. J Thorac Oncol (2011) 0.93
Patient subsets benefiting from adjuvant therapy following surgical resection of non-small cell lung cancer. Clin Cancer Res (2005) 0.83
New tumor, node, metastasis staging system for lung cancer. J Thorac Oncol (2009) 0.80
Adjuvant chemotherapy in early-stage non-small cell lung cancer. Semin Oncol (2005) 0.77